Lead Product(s) : Saposin C,Dioleoyl Phosphatidylserine
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a cell membrane phospholipid used for solid tumors and...
Product Name : BXQ-350
Product Type : Protein
Upfront Cash : Inapplicable
September 29, 2021
Lead Product(s) : Saposin C,Dioleoyl Phosphatidylserine
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable